Mutant BRAF-regulated transcription factors in melanoma progression
Mutant BRAF-regulated transcription factors in melanoma progression
批准号:
8913507
负责人:
Andrew Eric Aplin
金额:
$35.67万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-06-24 至 2020-05-31
关键词:
AddressAdjuvantAdverse effectsBRAF geneBioinformaticsCell Adhesion MoleculesCell Cycle ArrestCell Cycle ProgressionCellsChIP-seqCutaneous MelanomaDataDermalDiagnostic Neoplasm StagingDiseaseDisease ProgressionDown-RegulationEarly DiagnosisEarly treatmentEquilibriumEventGoalsGrowthHeterogeneityIn VitroIncidenceInterstitial CollagenaseLeadLinkMAPK3 geneMEKsMalignant - descriptorMalignant NeoplasmsMediator of activation proteinMelanoma CellModelingMonophenol MonooxygenaseMusMutateMutationNeoplasm MetastasisNevusPathway interactionsPatientsPlasticsPlayProgression-Free SurvivalsPropertyProtein-Serine-Threonine KinasesPublishingRegulationResistanceRoleSamplingSeriesSignal TransductionSkinSkin CancerStagingStructureTWIST1 geneTestingTherapeuticTranscriptTranscription Factor 3Transcription Repressor/CorepressorTumor stageUp-RegulationWorkcancer typeimprovedin vivoinhibitor/antagonistinnovationmelanomamimeticsmortalitymouse modelmutantneoplastic cellpluripotencypreventpublic health relevanceresearch studytraittranscription factortreatment strategytumor
中文摘要
描述(由申请人提供):黑色素瘤是最致命的皮肤癌。我们的目标是了解疾病进展的机制,以便更好地预测和识别侵袭性形式的黑色素瘤。丝氨酸/苏氨酸激酶BRAF在40-60%的黑色素瘤中发生体细胞突变。BRAF突变是导致MEK-ERK 1/2信号转导过度激活和黑色素瘤生长和侵袭的早期事件。虽然BRAF抑制剂现在是转移性突变V600 E BRAF黑色素瘤的一线疗法,但它们仅延迟死亡率,并且不用于辅助治疗。因此,我们必须加强对早期黑色素瘤生长和侵袭机制的认识,以提高早期诊断和预防转移的治疗策略。我们已经确定了转录因子,TWIST 1和FOXD 3,这是由突变的BRAF在黑色素瘤的调节。在这个提议中,我们试图确定TWIST 1和FOXD 3在黑色素瘤进展的早期阶段的侵袭和休眠中的作用。我们提出了三个具体目标,以确定TWIST 1在原发性黑色素瘤侵袭中的作用,使用3D皮肤模拟和突变BRAF小鼠模型,机械地理解FOXD 3对SOX 2(一种与诱导多能性相关的转录因子)的调节,并检查TWIST 1,FOXD 3和SOX 2之间的相互作用。在我们的实验完成时,我们期望已经证明突变BRAF调节的转录因子之间的相互作用控制黑色素瘤可塑性和转移级联步骤的基础机制。
英文摘要
DESCRIPTION (provided by applicant): Melanoma is the deadliest form of skin cancer. We aim to understand mechanisms underlying disease progression in order to better predict and identify aggressive forms of melanomas. The serine/threonine kinase, BRAF, is somatically mutated in 40-60% of melanomas. BRAF mutations are early events that lead to hyper-activation of MEK-ERK1/2 signaling and melanoma growth and invasion. While BRAF inhibitors are now first-line therapies for metastasized mutant V600E BRAF melanomas, they only delay mortality and are not being administered in the adjuvant setting. Thus, we must enhance our understanding of the mechanisms underlying growth and invasion of early-stage melanomas in order to improve early diagnosis and treatment strategies that prevent metastasis. We have identified transcription factors, TWIST1 and FOXD3, which are regulated by mutant BRAF in melanoma. In this proposal, we seek to determine the role of TWIST1 and FOXD3 in invasion and dormancy during the early steps of melanoma progression. We propose three Specific Aims to determine the role of TWIST1 in invasion of primary melanoma using 3D skin mimetic and mutant BRAF mouse models, to mechanistically understand FOXD3 regulation of SOX2 (a transcription factor linked to induced pluripotency), and to examine the interplay between TWIST1, FOXD3 and SOX2 in vivo. At the completion of our experiments, we expect to have demonstrated that the interplay between mutant BRAF-regulated transcription factors controls mechanisms that underlie melanoma plasticity and steps in the metastatic cascade.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma
-
批准号:10369699
-
项目类别:
-
资助金额:$53.54万
-
财政年份:2021
-
负责人:Andrew Eric Aplin
-
依托单位:
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma
-
批准号:10593130
-
项目类别:
-
资助金额:$52.58万
-
财政年份:2021
-
负责人:Andrew Eric Aplin
-
依托单位:
Training Program in Cancer Biology
-
批准号:10460513
-
项目类别:
-
资助金额:$23.0万
-
财政年份:2019
-
负责人:Andrew Eric Aplin
-
依托单位:
Training Program in Cancer Biology
-
批准号:10217049
-
项目类别:
-
资助金额:$24.79万
-
财政年份:2019
-
负责人:Andrew Eric Aplin
-
依托单位:
Training Program in Cancer Biology
-
批准号:10680403
-
项目类别:
-
资助金额:$14.24万
-
财政年份:2019
-
负责人:Andrew Eric Aplin
-
依托单位:
Training Program in Cancer Biology
-
批准号:10020942
-
项目类别:
-
资助金额:$26.92万
-
财政年份:2019
-
负责人:Andrew Eric Aplin
-
依托单位:
Mutant BRAF-regulated transcription factors in melanoma progression
-
批准号:9264500
-
项目类别:
-
资助金额:$35.69万
-
财政年份:2015
-
负责人:Andrew Eric Aplin
-
依托单位:
Targeted therapies in cutaneous melanoma
-
批准号:10395432
-
项目类别:
-
资助金额:$36.31万
-
财政年份:2014
-
负责人:Andrew Eric Aplin
-
依托单位:
Targeted therapies in mutant BRAF melanoma
-
批准号:9490278
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2014
-
负责人:Andrew Eric Aplin
-
依托单位:
Targeted therapies in mutant BRAF melanoma
-
批准号:8774480
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2014
-
负责人:Andrew Eric Aplin
-
依托单位:
Targeted therapies in cutaneous melanoma
-
批准号:10625980
-
项目类别:
-
资助金额:$36.31万
-
财政年份:2014
-
负责人:Andrew Eric Aplin
-
依托单位:
Targeted therapies in mutant BRAF melanoma
-
批准号:8891392
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2014
-
负责人:Andrew Eric Aplin
-
依托单位:
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
-
批准号:10451609
-
项目类别:
-
资助金额:$36.31万
-
财政年份:2012
-
负责人:Andrew Eric Aplin
-
依托单位:
Request for Supplemental Funds aligned to CA160495
-
批准号:9902022
-
项目类别:
-
资助金额:$12.45万
-
财政年份:2012
-
负责人:Andrew Eric Aplin
-
依托单位:
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
-
批准号:10212280
-
项目类别:
-
资助金额:$37.05万
-
财政年份:2012
-
负责人:Andrew Eric Aplin
-
依托单位:
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors
-
批准号:8464030
-
项目类别:
-
资助金额:$30.23万
-
财政年份:2012
-
负责人:Andrew Eric Aplin
-
依托单位:
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors
-
批准号:9021024
-
项目类别:
-
资助金额:$1.42万
-
财政年份:2012
-
负责人:Andrew Eric Aplin
-
依托单位:
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors
-
批准号:8634058
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2012
-
负责人:Andrew Eric Aplin
-
依托单位:
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors
-
批准号:8827699
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2012
-
负责人:Andrew Eric Aplin
-
依托单位:
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors
-
批准号:8720414
-
项目类别:
-
资助金额:$3.89万
-
财政年份:2012
-
负责人:Andrew Eric Aplin
-
依托单位:
海外基金